A Case-Based Approach to Targeted Therapy with COTELLIC (cobimetinib) and ZELBORAF (vemurafenib) for BRAFV600E/K Mutation-Positive Unresectable or Metastatic Melanoma
This clinical presentation is designed for oncology nurses who may help treat patients with COTELLIC and ZELBORAF and will review clinical data and safety profile information.
Grace Cherry, MSN
Los Angeles, CA
Register at: www.medforcereg.net/SGEN8742